Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV301 Vaccine with Nivolumab and Chemo in Resectable Liver-Limited Metastatic CRC
NCT03547999Phase 2Terminated
- Sponsor
- Patrick Boland
- Start
- Jun 2018
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CV301 in colorectal cancer (metastatic) (mCRC) (2 arms), sponsored by Patrick Boland. Primary endpoint: Overall Survival at 3 years. Started Jun 2018; status: terminated.
02
Drugs
CV301
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03547999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547999.